Gene Therapy Stocks List
|2019-09-16||CRXM||Pocket Pivot||Bullish Swing Setup|
|2019-09-16||CRXM||New 52 Week High||Strength|
|2019-09-16||CRXM||Crossed Above 20 DMA||Bullish|
|2019-09-16||OXBDF||Narrow Range Bar||Range Contraction|
|2019-09-16||PRVCF||Lower Bollinger Band Walk||Weakness|
|2019-09-16||PRVCF||50 DMA Resistance||Bearish|
|2019-09-16||PRVCF||20 DMA Resistance||Bearish|
In the medicine field gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease. The first attempt at modifying human DNA was performed in 1980 by Martin Cline, but the first successful nuclear gene transfer in humans, approved by the National Institutes of Health, was performed in May 1989. The first therapeutic use of gene transfer as well as the first direct insertion of human DNA into the nuclear genome was performed by French Anderson in a trial starting in September 1990.
Between 1989 and February 2016, over 2,300 clinical trials were conducted, with more than half of them in phase I.
Not all medical procedures that introduce alterations to a patient's genetic makeup can be considered gene therapy. Bone marrow transplantation and organ transplants in general have been found to introduce foreign DNA into patients. Gene therapy is defined by the precision of the procedure and the intention of direct therapeutic effect.